Viridian Therapeutics Earnings Reports

Viridian Therapeutics reported positive topline phase 3 data for veligrotug in patients with active and chronic thyroid eye disease (TED), advanced its REVEAL-1 and REVEAL-2 phase 3 clinical trials for VRDN-003, and anticipates proof-of-concept clinical data for VRDN-006 in Q3 2025. The company's cash position was strong at $717.6 million as of December 31, 2024, providing a cash runway into the second half of 2027.

Viridian Therapeutics reported positive topline phase 3 data for veligrotug and initiated two global phase 3 clinical trials of subcutaneous VRDN-003. The company's cash runway extends into the second half of 2027, supported by net proceeds of $243.2 million from a public offering.

Viridian Therapeutics reported solid progress in its TED portfolio, with VRDN-001 phase 3 trials exceeding enrollment targets and VRDN-003 trials planned to initiate this month. All timelines within the FcRn portfolio remain on track, and the company anticipates submitting an IND for VRDN-006 by year-end and reporting NHP data for VRDN-008 in the second half of the year. Cash, cash equivalents, and short-term investments were $571.4 million as of June 30, 2024, providing a cash runway into the second half of 2026.

Viridian Therapeutics reported a net loss of $48.5 million for the first quarter ended March 31, 2024. The company's cash, cash equivalents, and short-term investments were $613.2 million as of March 31, 2024, which is expected to fund operations into the second half of 2026.

Viridian Therapeutics reported a cash balance of $477.4 million as of December 31, 2023. Key milestones include the anticipation of VRDN-001 Phase 3 topline clinical data readouts in mid-year and year-end 2024, and the expected start of the subcutaneous VRDN-003 pivotal program in mid-year 2024.

Viridian Therapeutics reported its Q3 2023 financial results, highlighting the continuation of enrollment in the THRIVE and THRIVE-2 clinical trials for thyroid eye disease (TED) patients, the expected selection of a lead subcutaneous TED program by the end of 2023, and the advancement of a novel preclinical portfolio of FcRn inhibitors. The company also announced the appointment of Stephen Mahoney as President and CEO and closed a private placement of approximately $185 million to fund pipeline development and extend operating cash runway into 2026.

Viridian Therapeutics reported a net loss of $68.2 million for the first quarter of 2023, compared to a net loss of $25.7 million for the same period last year. Research and development expenses were $50.7 million, including a one-time $15.0 million upfront payment to Enable Injections. Cash, cash equivalents, and short-term investments were $373.9 million as of March 31, 2023.

Viridian Therapeutics reported its Q4 2022 financial results, with a net loss of $45.8 million. The company's cash, cash equivalents, and short-term investments totaled $424.6 million as of December 31, 2022, and they believe it will be sufficient to fund operations into the second half of 2025.

Viridian Therapeutics reported positive initial clinical data from the Phase 1/2 trial of VRDN-001 in TED patients and VRDN-002 in healthy volunteers. The company ended the quarter with $161.2 million in cash, cash equivalents, and short-term investments, providing a cash runway into 2024.

Viridian Therapeutics reported its first quarter 2022 financial results, highlighting the ongoing clinical trials for VRDN-001 and VRDN-002 and the expectation of top line data in the coming months. The company ended the quarter with $175 million in cash, cash equivalents, and short-term investments, expected to fund operations into 2024.

Viridian Therapeutics reported its Q4 2021 financial results, with a net loss of $28.9 million. The company's cash and investments totaled $197 million, expected to fund operations into 2024. The company is advancing its pipeline of therapeutic candidates for thyroid eye disease.

Viridian Therapeutics reported financial results for the third quarter ended September 30, 2021. The company's cash, cash equivalents and short-term investments were $213.8 million as of September 30, 2021. Net loss was $14.03 million for the quarter.

Viridian Therapeutics reported $109.3 million in cash, cash equivalents and short-term investments as of June 30, 2021. The company's net loss was $18.0 million for the second quarter of 2021.

Viridian Therapeutics reported its first quarter 2021 financial results, highlighting progress in its VRDN-001 and VRDN-002 programs for Thyroid Eye Disease (TED) and a cash position of $117 million. The company's net loss for the quarter was $18.5 million, with increased R&D and G&A expenses compared to the same period in 2020.

Viridian Therapeutics reported a net loss of $90.7 million for the fourth quarter of 2020. The company's cash, cash equivalents, and short-term investments totaled $127.6 million as of December 31, 2020, providing runway into the second half of 2023.

Miragen Therapeutics reported a net loss of $5.5 million for the third quarter of 2020. The company completed the acquisition of Viridian Therapeutics and closed a private placement financing, resulting in approximately $144 million in cash on hand and an estimated cash runway through 2023.

miRagen Therapeutics reported a net loss of $6.4 million, or $0.12 per share, for the second quarter of 2020. Cash and cash equivalents were $30.6 million as of June 30, 2020, and the company believes its cash will fund operations into Q3 2021.

miRagen Therapeutics reported $36.1 million in cash and cash equivalents as of March 31, 2020, with an anticipated cash runway into Q3 2021. The company's net loss was $8.0 million, or $0.18 per share, for the first quarter of 2020.

miRagen Therapeutics reported a net loss of $10.1 million, or $0.31 per share, for the fourth quarter of 2019. The company's cash, cash equivalents, and short-term investments were $26.8 million as of December 31, 2019. Revenue for the fourth quarter was $0.9 million, and research and development expenses were $8.4 million.